RECRUITINGOBSERVATIONAL

NOACs Use in AF or VTE (SUNSHINE Registry)

Outcomes regiStry for Non-vitamin k Antagonist Oral anticoagUlants treatmeNt in variouS tHrombotIc dIseases for Better cliNical practicE (SUNSHINE)

About This Trial

The outcomes regiStry for non-vitamin k antagonist oral anticoagUlants treatmeNt in variouS tHrombotIc dIseases for better cliNical practicE (SUNSHINE) is a multicenter, prospective, observational non-interventional inpatient/outpatient disease registry to assess the utilization of Non-vitamin k antagonist oral anticoagulants (NOACs), and associated outcomes. The SUNSHINE registry will focus on the collection and analysis of observational data in medical records from hospital information system (HIS) to evaluate the outcomes related with these NOACs when applied in extensive patient populations outside of clinical research studies. The registry will also allow for mainly combining the atrial fibrillation (AF) and venous thromboembolism (VTE) databases. In brief, the SUNSHINE registry will provide important information on the outcomes of NOACs in routine practice and gather further information on its safety and effectiveness.

Who May Be Eligible (Plain English)

Who May Qualify: - Patients with clinically diagnosed with AF (eg, by electrocardiogram, Holter monitoring, implanted device, etc) or VTE (initial or recurrent acute VTE) - Patients who use OACs therapy (including NOAC or VKA) within the preceding 3 months - Patients can be enrolled from both inpatient or outpatient settings Who Should NOT Join This Trial: - AF resulting from reversible cause factors (e.g., thyroid disease, postoperative AF) - Patients with a diagnosis of valvular AF (valvular AF mainly refers to patients with AF that have either rheumatic valvular disease \[predominantly mitral stenosis\] or mechanical heart valves) - Patients participating in an ongoing clinical trial in AF or VTE - Have Multiple anticoagulation indications apart from AF or VTE - Patients with incomplete information (illogical data, missing or insufficient data) Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * Patients with clinically diagnosed with AF (eg, by electrocardiogram, Holter monitoring, implanted device, etc) or VTE (initial or recurrent acute VTE) * Patients who use OACs therapy (including NOAC or VKA) within the preceding 3 months * Patients can be enrolled from both inpatient or outpatient settings Exclusion Criteria: * AF resulting from reversible cause factors (e.g., thyroid disease, postoperative AF) * Patients with a diagnosis of valvular AF (valvular AF mainly refers to patients with AF that have either rheumatic valvular disease \[predominantly mitral stenosis\] or mechanical heart valves) * Patients participating in an ongoing clinical trial in AF or VTE * Have Multiple anticoagulation indications apart from AF or VTE * Patients with incomplete information (illogical data, missing or insufficient data)

Treatments Being Tested

OTHER

Patients with Atrial Fibrillation (AF) or venous thromboembolism (VTE)

Patients with AF or VTE; OAC treatment patterns according to patient demographics, clinical factors, risk stratification, geographic regions, local NOAC medical insurance policy and NOACs availability

Locations (1)

Henan Provincial People's Hospital

Zhengzhou, Henan, China